Isoptin

Verapamil Hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral tablet and injectable solution for intravenous and oral use. It is employed to manage hypertension, angina pectoris, and certain supraventricular tachyarrhythmias in adult patients. GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoptin (verapamil hydrochloride) acts on the cardiovascular system to control blood pressure, heart rhythm, and chest pain. - Hypertension: lowers systemic blood pressure by causing peripheral vasodilation. - Angina pectoris: reduces myocardial oxygen demand through decreased contractility and heart rate. - Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter): slows atrioventricular nodal conduction to restore regular rhythm.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs. - Constipation: reduced bowel motility. - Dizziness: sensation of light‑headedness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Bradycardia: markedly slowed heart rate. - Hypotension: significant drop in blood pressure. - Heart block: impairment of electrical conduction. - Hepatotoxicity: abnormal liver function tests. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Cardiac function: assess for existing heart failure or conduction disorders. - Liver disease: adjust use in moderate to severe hepatic impairment. - Electrolyte imbalance: correct potassium or magnesium abnormalities. - Drug discontinuation: taper gradually to avoid rebound hypertension. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store below 25°C: keep in the original pack, protect from moisture.

Verapamil may alter the pharmacokinetics or pharmacodynamics of several agents.

Major Interactions (Avoid): - Beta‑blockers: risk of severe bradycardia and AV block. - Digoxin: increased serum levels leading to toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly elevated verapamil concentrations.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin): heightened risk of myopathy. - Antidiabetic drugs (e.g., insulin, sulfonylureas): possible hypoglycaemia. - Antihypertensives (e.g., ACE inhibitors, diuretics): additive blood pressure lowering effect.